Design Cells News Today

CBS 58 is your local source for the Milwaukee news, Milwaukee weather, and Milwaukee sports.

The results were the longest survival follow-up ever reported for a phase 3 trial for biliary tract cancer.

In the RUBY phase 3 trial, dostarlimab (Jemperli; GSK) with niraparib (Zejula; GSK) had significant progression free survival compared to the standard of care.

ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.

/PRNewswire/ -- GN, the global leader in hearing aid innovation, and Soundly, a consumer education resource for hearing wellness, have joined forces once again...

Patients with myelodysplastic syndrome harboring a TP53 mutation experienced a survival benefit with allogeneic hematopoietic cell transplantation compared with non-HCT treatment regardless of TP53 allelic status.

In a trial assessing subcutaneous OCTA101 in patients with severe hemophilia A, promising results in pharmacokinetics and efficacy were overshadowed by safety concerns.

Some people seem to think the risk posed by preservatives is greater than the risk posed by microbial contamination. They are wrong. 

Patients with paroxysmal nocturnal hemoglobinuria (PNH) who had suboptimal response to eculizumab can switch to pegcetacoplan for a cost-effective alternative, according to. acost analysis.

Immune thrombotic thrombocytopenic purpura (TTP) can be treated safely and effectively with caplacizumab.